Search clinical trials for: Naïve patients

Total 106285 results

Regeneron Pharmaceuticals

Not yet recruiting

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (SPECTRUM-US)

Visual Impairment | Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD) | Wet Age-related Macular Degeneration (AMD)
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Joshua Palmer
Genentech, Inc.

Recruiting

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE)

NSCLC | Lung Cancer | Brain Metastases

United States
AstraZeneca

Not yet recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)

Diffuse Large B-Cell Lymphoma
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Nanchang University

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Nanchang University

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2)

Non Small Cell Lung Cancer

Italy
Assistance Publique - Hôpitaux de Paris

Recruiting

IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima® (PRIME)

Inflammatory Bowel Diseases

France
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
M.D. Anderson Cancer Center
Loxo Oncology, Inc.; The Leukemia and Lymphoma Society

Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Leukemia

United States
M.D. Anderson Cancer Center
National Institutes of Health (NIH)

Recruiting

A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)

Cancer | Pediatric ALL

United States
Myung-Ju Ahn

Recruiting

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

NSCLC

Korea, Republic of
Peking Union Medical College Hospital

Not yet recruiting

A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients

HIV-1-infection
Providence Health & Services
Merck Sharp & Dohme LLC; Eisai Inc.

Recruiting

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Melanoma, Uveal

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (BELIEVE-01)

Diffuse Large B Cell Lymphoma (DLBCL)

China
National Liver Institute, Egypt
Future pharmaceutical industries

Recruiting

Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management (NILE)

Helicobacter Pylori

Egypt
Scott Antonia

Recruiting

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101)

Lung Cancer Metastatic

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Peking University First Hospital

Recruiting

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China (BDTAF)

Chronic Hepatitis B | Chronic Hepatitis C

China
Assistance Publique - Hôpitaux de Paris

Recruiting

Baricitinib in Patients With Relapsing or naïve Dermatomyositis (BIRD)

Dermatomyositis

France
Conjupro Biotherapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Solid Tumor

United States
Odense University Hospital
University of Southern Denmark; Region of Southern Denmark

Recruiting

Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases (FRONT)

Rheumatoid Arthritis | Crohn Disease | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis | Pulmonary Sarcoidosis

Denmark
Yonsei University

Not yet recruiting

Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease (VEDOKO-IIT)

Crohn's Disease and Ulcerative Colitis

Korea, Republic of
Paolo Ghia

Recruiting

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL (FIGHT)

Chronic Lymphocytic Leukemia

Italy
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
Paolo Ghia

Recruiting

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE)

Chronic Lymphocytic Leukemia (CLL)

Italy
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients (ASCERTAIN)

Non-muscle Invasive Bladder Cancer

China
Muhammad Furqan
AstraZeneca

Recruiting

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
Jun Zhang, MD, PhD

Recruiting

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

NSCLC Stage IV | NSCLC, Recurrent

United States
Yale University
Apexigen America, Inc.

Recruiting

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Advanced Melanoma

United States
Second Affiliated Hospital, School of Medicine,...
Hangzhou Medical Biotechnology Co., Ltd; CyTIX.Inc

Recruiting

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue | Vaccines | Immunologic Factors

China
University Hospital, Bonn
Maximilian Kiebs, M.S.; Clemens Mielacher, M.S.

Recruiting

Repetitive Transcranial Magnetic Stimulation in Pharmaco-naïve Patients With Major Depression (NAIV)

Major Depressive Disorder

Germany
Peter MacCallum Cancer Centre, Australia

Recruiting

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE)

Follicular Lymphoma

United States, Australia
University of Leeds
Samsung Bioepis Co., Ltd.

Not yet recruiting

Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification (TEEMS)

Rheumatoid Arthritis

United Kingdom
Azienda Policlinico Umberto I

Recruiting

An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge) (RalAge2)

Hiv

Italy
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC; BioNTech SE; Oncovir, Inc.

Recruiting

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Lymphocytic Leukemia

United States
ImmunityBio, Inc.

Recruiting

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (REACTS)

Severe Aplastic Anemia (SAA)

Japan, Korea, Republic of, China, Taiwan
Radiomedix, Inc.
Orano Med LLC

Active, not recruiting

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (ALPHAMEDIX02)

Neuroendocrine Tumors

United States
Novartis Pharmaceuticals

Active, not recruiting

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

Relapse Remitting Multiple Sclerosis

United States, Puerto Rico
Fundacion Oncosur
Apices Soluciones S.L.

Active, not recruiting

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

Invasive Bladder Cancer

Spain
Hoffmann-La Roche

Active, not recruiting

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Carcinoma, Non-Small-Cell Lung

China
Acerta Pharma BV
National Institutes of Health (NIH)

Active, not recruiting

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Genentech, Inc.

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Korea, Republic of, Taiwan, France, Serbia
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Chronic Spontaneous Urticaria

China, France, Spain, Argentina, Germany, Japan, United States, Canada, Hungary, Russian Federation, United Kingdom
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type

China

3

Subscribe